Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Early Feasibility Study of Low Intensity Focused Ultrasound Neuromodulation in Patients With Fibromyalgia

NCT07934667 is registered in ClinicalTrials.gov with University of Virginia as lead sponsor.

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, 14-day trial. Card required. Your first charge is when the trial ends. See pricing

Get the NCT07934667 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Follow this trial by email

Registry record

As filed in ClinicalTrials.gov.

Title
Early Feasibility Study of Low Intensity Focused Ultrasound Neuromodulation in Patients With Fibromyalgia
Lead sponsor
University of Virginia
Phase
Not applicable
Overall status
Not yet recruiting
Start date
January 15, 2027
Completion date
April 1, 2029
Enrollment
40 (estimated)
Sites
Not reported

Conditions

As the registry lists them; a condition with its own page is linked.

Arms

As registered; 2 arms.

  • Low Intensity Focused Ultrasound + Savoring Meditation (liFU+SM) ExperimentalLow intensity focused ultrasound + Savoring Meditation
  • Low Intensity Focused Ultrasound Active comparatorLow Intensity Focused Ultrasound

Primary endpoints

Registered primary outcome measures; 4 primary.

  • Safety of liFU intervention At Session 7 (Week 3), at Sessions 8-11 (Weeks 3-6; immediately before and after each intervention and 24h after each intervention), weekly throughout weeks 7-11 and at Session 12 (Week 11).

    Number of treatment-related unexpected adverse events and serious adverse events

  • Study recruitment rate Assessed from screening (Session 1; week -1) to enrollment (Session 2; week 0).

    Number of participants enrolled divided by number screened.

  • Study adherence Assessed from enrollment (Session 2; week 0) to follow up (Session 12; week 11).

    Number of participants to complete all Phase 1 and Phase 2 intervention sessions

  • Study retention Assessed from enrollment (Session 2; week 0) to follow up (Session 12; week 11).

    Number of enrolled participants retained through the entirety of the study

Lead sponsor's other trials

University of Virginia, most recent start first.

Similar trials

Same condition (Fibromyalgia) and phase, most recent start first.